Specialties

Advanced BCC: histological subtype and time to complete response may predict tumour recurrence

Presented By

Dr Maria Mannino, Catholic University of the Sacred Heart, Italy

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:02

Trastuzumab deruxtecan also effective in patients with brain metastases

Presented By

Dr Nancy Lin, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, DESTINY-Breast12

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:37

High pCR rates with dual neoadjuvant immunotherapy in TIL-high TNBC

Presented By

Dr Iris Nederlof, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, BELLINI

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:35

Local HER2 IHC0 is often HER2-low or -ultralow

Presented By

Prof. Giuseppe Viale, University of Milan, Italy

Trial

Phase 3, DESTINY-Breast06

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:32

First-line capivasertib improves PFS but not OS in metastatic TNBC

Presented By

Prof. Heather McArthur, UT Southwestern Medical Center, TX, USA

Trial

Phase 3, CAPItello-290

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:27

Breastfeeding does not increase the risk of breast cancer recurrence

Presented By

Dr Fedro Peccatori, European Institute of Oncology, Italy; Dr Eva Blondeaux, University of Genova, Italy

Trial

POSITIVE, BRCA BCY Collaboration

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:23

More highlights in Breast Cancer

Trial

HERA, NATALEE, KEYNOTE-522, HypoG-01

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:20

Adjuvant durvalumab does not improve survival in completely resected NSCLC

Presented By

Prof. Glenwood Goss, Ottawa Hospital, Canada

Trial

Phase 3, BR.31

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:15

NVL-655: a promising new option in pre-treated, drug-resistant ALK-mutated NSCLC

Presented By

Dr Alexander Drilon, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 1/2, ALKOVE-1

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:13

Relatlimab addition benefits only a subgroup of metastatic NSCLC

Presented By

Prof. Nicolas Girard, Institut Curie, France

Trial

Phase 2, RELATIVITY-104

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:11

More highlights in Lung Cancer

Trial

Phase 3, MARIPOSA, MARIPOSA-2

Type

Peer-reviewed article

4 November 2024 12:08

Neoadjuvant nivolumab/ipilimumab improves DMFS in stage III resectable melanoma

Presented By

Dr Minke Lucas, Netherlands Cancer Institute, the Netherlands

Trial

Phase 3, NADINA

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:00

New neoadjuvant combinations in stage III melanoma

Presented By

Dr Alexander Menzies, University of Sydney, Australia

Trial

Phase 1/2, KEYMAKER-U02

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:58

Long-term benefit of nivolumab, ipilimumab, and pembrolizumab: 10-year survival data

Trial

Phase 3, KEYNOTE-006, CheckMate 067

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:53

Rethinking immune rechallenge: Tivozanib monotherapy emerges as a promising post-ICI option in metastatic RCC

Presented By

Prof. Toni Choueiri, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, TiNivo-2

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:52

Faecal transplants show promise in enhancing metastatic RCC treatment

Presented By

Dr Chiara Ciccarese, Agostino Gemelli University Policlinic, Italy

Trial

Phase 2, TACITO

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:44

More highlights in Renal Cell Carcinoma

Trial

LITESPARK-005, SUNNIFORECAST

Type

Peer-reviewed article

4 November 2024 11:42

TACITO: Does FMT improve ICI plus VEGFR TKI therapy in mRCC?

Presented By

Dr Gianluca Ianiro, Agostino Gemelli University Policlinic, Italy

Trial

Phase 2, TACITO

Conference

UEGW 2024

Type

News article

15 October 2024 10:13

Reclassification of AML Subtypes and Risk in Light of ICC and ELN2022

17 September 2024 13:51

OS benefit in ARMANI, but is it worth it?

Presented By

Dr Giovanni Randon, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

Trial

Phase 3, ARMANI

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 12:08

SPOTLIGHT on new targets in immunotherapy: claudin 18.2

Presented By

Prof. Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, SPOTLIGHT

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 12:03

AI facilitates early detection of hepatocellular carcinoma

Presented By

Dr Kin Nam Kwok, Hong Kong University, Hong Kong

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:59

Encouraging efficacy of anti-claudin 18.2 ADC in G/GEJ cancer

Presented By

Dr Jia Liu, St Vincent’s Hospital Sydney, Australia

Trial

Phase 1

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:58

Durvalumab plus chemotherapy enhances 3-year survival in advanced biliary tract cancer

Presented By

Prof. Do-Youn Oh, Seoul National University, Korea

Trial

Phase 3, TOPAZ-1

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:53

New analyses validate TAP and CPS scores for PD-L1 expression

Presented By

Prof. Markus Moehler; Prof. Eric Raymond

Trial

Phase 3, RATIONALE-305; RATIONALE-306

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:39

KEYNOTE-585: negative trial, but long-term benefit in PD-L1-high/MSI subgroups?

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, KEYNOTE-585

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:30

MINOTAUR: Promising phase 1 data for lunresertib plus FOLFIRI

Presented By

Dr Elisa Fontana, Sarah Cannon Research Institute, UK

Trial

Phase 1, MINOTAUR

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:09

The landscape of TP53 mutations and their prognostic impact in CLL

Presented By

Dr Consuelo Bertossi, University Hospital Ulm, Germany

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 15:11

Can golcadomide plus R-CHOP become the first-line standard of care in high-risk BCL?

Presented By

Dr Marc Hoffman, The University of Kansas Cancer Center, KS, USA

Trial

Phase 1, CC-220-DLBCL-001

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

High survival rates following atezolizumab consolidation in DLBCL

Presented By

Dr Marcel Nijland, University Medical Center Groningen, the Netherlands

Trial

Phase 2, HOVON 151

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL

Presented By

Prof. Paolo Ghia, University Vita-Salute San Raffaele, Italy

Trial

Phase 3, SEQUOIA

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

EPCORE CLL-1: Promising data for epcoritamab in high-risk Richter’s transformation

Presented By

Prof. Arnon Kater, University of Amsterdam, the Netherlands

Trial

Phase 1/2, EPCORE CLL-1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

Updates from the EBMT Lymphoma Working Group: outcomes after allo- and auto-SCT for T-cell lymphoma subtypes

Presented By

Dr Evgenii Shumilov, University of Münster, Germany

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

ECHO: Can we expect a novel standard of care in newly diagnosed MCL?

Presented By

Prof. Michael Wang, University of Texas, TX, USA

Trial

Phase 3, ECHO

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:26

Clinically meaningful outcomes for mosunetuzumab across follicular lymphoma subgroups

Presented By

Dr Sarit Assouline, Jewish General Hospital, Canada

Trial

Phase 1/2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:26

Encouraging data for ELA026 to treat secondary haemophagocytic lymphohistiocytosis

Presented By

Dr Abhishek Maiti, MD Anderson Cancer Center, TX, USA

Trial

Phase 1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

PhALLCON: Third-generation TKI superior to first-generation TKI in Ph+ ALL

Presented By

Prof. Jose Maria Ribera, Josep Carreras Leukaemia Research Institute, Spain

Trial

Phase 3, PhALLCON

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

APOLLO: ATRA plus ATO meets expectations in high-risk APL

Presented By

Prof. Uwe Platzbecker, Leipzig University Hospital, Germany

Trial

Phase 3, TUD-APOLLO-064

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

Excellent phase 3 results for asciminib in chronic myeloid leukaemia

Presented By

Prof. Andreas Hochhaus, Jena University Hospital, Germany

Trial

Phase 3, ASC4FIRST

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

AUGMENT-101: Revumenib trial in KMT2Ar leukaemia stopped early for efficacy

Presented By

Dr Ibrahim Aldoss, City of Hope National Medical Center, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:24

FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML

Presented By

Dr Wei-Ying Jen, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:20

CD40/CD47 inhibitor shows promise in high-risk MDS and AML

Presented By

Prof. Amer Zeidan, Yale University, CT, USA

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

ENHANCE: Magrolimab does not ameliorate health outcomes in high-risk MDS

Presented By

Dr David Sallman, Moffitt Cancer Center, FL, USA

Trial

Phase 3, ENHANCE

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Can MRD-guided azacitidine treatment improve outcomes in AML and MDS?

Presented By

Dr Anne Sophie Kubasch, University of Leipzig, Germany

Trial

Phase 2, RELAZA2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Can WGTS replace standard-of-care diagnostics in AML?

Presented By

Dr Anna Staffas, University of Gothenburg, Sweden

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial

Presented By

Prof. Thierry Facon, University of Lille, France

Trial

Phase 3, IMROZ

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

PERSEUS: High MRD negativity rates with D-VRd and consolidation therapy and D-R maintenance in MM

Presented By

Prof. Pieter Sonneveld, Erasmus University Medical Center, the Netherlands

Trial

Phase 3, PERSEUS

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

Post-intensification data confirm superiority of quadruple therapy in MM

Presented By

Prof. Marc Raab, University Hospital Heidelberg, Germany

Trial

Phase 3, GMMG-HD7

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

Promising phase 1 results for novel CAR T-cell therapy in MM

Presented By

Dr Binod Dhakal, Medical College of Wisconsin, WI, USA

Trial

Phase 1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

DREAMM 8: Belantamab mafodotin offers hope for patients with RRMM

Presented By

Prof. Meletious Dimopoulos, University of Athens, Greece

Trial

Phase 3, DREAMM 8

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:16

Meet the Expert: Samantha Nier on the added value of patient advocacy –not just for patients

Expert

Samantha Nier, Acute Leukemia Advocates Network

1 August 2024 14:16

No survival benefit of tumour debulking for patients with multi-organ metastatic CRC

Presented By

Dr Elske Gootjes, Radboudumc, the Netherlands

Trial

Phase 3, ORCHESTRA

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:53

Benefit of first-line nivolumab/ipilimumab in MSI-H/dMMR metastatic CRC

Presented By

Prof. Heinz-Josef Lenz, University of Southern California Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 3, CheckMate 8HW

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:44

Neoadjuvant checkpoint blockade in MSI-H/dMMR CRC

Trial

Phase 1/2, NICHE-2, NEOPRISM-CRC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:36

CodeBreaK 300: Promising survival trends in KRAS G12C-mutated mCRC

Presented By

Prof. Marwan Fakih, City of Hope Comprehensive Cancer Center, CA, USA

Trial

Phase 3, CodeBreaK 300

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:26

FLOT outperforms CROSS in resectable oesophageal cancer

Presented By

Prof. Jens Höppner, University of Bielefeld, Germany

Trial

Phase 3, ESOPEC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:14

Nivolumab/ipilimumab combination outperforms TKIs in unresectable HCC

Presented By

Dr Peter Galle, Universitätsmedizin Mainz, Germany

Trial

Phase 3, CheckMate 9DW

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:10

No advantage of neoadjuvant radiochemotherapy over neoadjuvant chemotherapy in borderline resectable pancreatic cancer

Presented By

Dr Masafumi Ikeda, National Cancer Center Hospital East, Japan

Trial

Phase 3, GABARNANCE

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:06

Benefit of abemaciclib plus fulvestrant after progression on a CDK4/6 inhibitor

Presented By

Prof. Kevin Kalinsky, Emory School of Medicine, GA, USA

Trial

postMONARCH

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:02

ctDNA is prognostic of worse outcomes for CDK4/6 therapy

Presented By

Prof. Sherene Loi, Peter MacCallum Cancer Centre, Australia

Trial

Phase 3, monarchE

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:56

Adjuvant avelumab significantly improves survival in early TNBC

Presented By

Prof. Pierfranco Conte, University of Padova, Italy

Trial

Phase 3, A-BRAVE

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:53

High pCR rate after neoadjuvant Dato-DXd plus durvalumab therapy

Presented By

Dr Jane Meisel, Emory School of Medicine, GA, USA & Dr Rebecca Shatsky, University of California San Diego, CA, USA

Trial

I-SPY2.2

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:38

Osimertinib significantly improves PFS in patients with unresectable stage III EGFR-mutated NSCLC

Presented By

Prof. Suresh Ramalingam, Emory School of Medicine, GA, USA

Trial

Phase 3, LAURA

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:30

First-line lorlatinib provides unprecedented improvement for patients with advanced ALK-positive NSCLC

Presented By

Prof. Benjamin Solomon, Peter MacCallum Cancer Centre, Australia

Trial

Phase 3, CROWN

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:28

Comparable benefit of video- and in-person-delivered palliative care

Presented By

Dr Joseph Greer, Harvard Medical School, MA, USA

Trial

REACH PC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:25

Consolidation with durvalumab improves survival in LS-SCLC

Presented By

Dr David Spigel, Sarah Cannon Research Institute, TN, USA

Trial

Phase 3, ADRIATIC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:23

Subcutaneous amivantamab non-inferior and more convenient than intravenous amivantamab

Presented By

Dr Natasha Leighl, Princess Margaret Cancer Centre, Canada

Trial

Phase 3, PALOMA-3

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:19

Highly significant event-free survival benefit with neoadjuvant nivolumab/ipilimumab in stage III melanoma

Presented By

Prof. Christian Blank, Antoni van Leeuwenhoek, the Netherlands

Trial

Phase 3, NADINA

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:16

Neoadjuvant intralesional daromun improves relapse-free survival in stage III melanoma

Presented By

Prof. Axel Hauschild, Universitätsklinikum Schleswig-Holstein, Germany

Trial

Phase 3, PIVOTAL

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:13

Intratumoural tilsotolimod shows no benefit for advanced refractory melanoma

Presented By

Prof. Caroline Robert, Gustave Roussy, France

Trial

Phase 3, ILLUMINATE-301

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:09

Immune-enhancing nutrition does not affect complication rate of radical cystectomy

Presented By

Prof. Jill Hamilton-Reeves, University of Kansas Medical Center, KS, USA

Trial

Phase 3, SWOG S1600

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:05

Biomarkers for treatment of renal cell carcinoma

Trial

Phase 3, CLEAR, KEYNOTE-426, IMmotion010

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:00

ctDNA changes as biomarker for pembrolizumab response in advanced urothelial carcinoma

Presented By

Prof. Thomas Powles, Barts Cancer Institute, UK

Trial

Phase 3, KEYNOTE-361

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:51

Highest efficacy of nivolumab/chemotherapy in lymph-node-only metastatic urothelial carcinoma

Presented By

Prof. Matthew Galsky, Tisch Cancer Institute, NY, USA

Trial

Phase 3, CheckMate 901

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:48

Metformin does not prevent progression of low-risk prostate cancer

Presented By

Dr Anthony Joshua, Princess Margaret Cancer Centre, Canada

Trial

Phase 3, MAST

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:46

Baseline ctDNA has both prognostic and predictive value in mCRPC

Presented By

Prof. Johann de Bono, Royal Marsden Hospital, UK

Trial

Phase 3, PSMAfore

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:44

Oxybutynin significantly decreases frequency and severity of hot flashes in men on ADT

Presented By

Dr Brad Stish, Mayo Clinic, MN, USA

Trial

Phase 2, Alliance 222001

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:41

Subcutaneous nivolumab may benefit patients across many indications

Expert

Dr Saby George, Roswell Park Cancer Institute, Buffalo, NY, USA

Trial

Phase 3, CheckMate 67T

Conference

ASCO GU 2024

17 July 2024 12:37

Meet the Trialist: Prof. Giuseppe Curigliano on DESTINY-Breast06

Expert

Prof. Giuseppe Curigliano, University of Milan, Italy

Trial

Phase 3, DESTINY-Breast06

Conference

ASCO 2024

24 June 2024 15:38

CircPRELID2 promotes renal cell carcinoma via miR-22-3p/ETV1 cascade

14 June 2024 13:52

Minimal incidence of severe end-stage kidney disease following SABR for localised primary kidney cancer

14 June 2024 13:50

Comparing standard and modified ipilimumab with nivolumab in advanced renal cell carcinoma treatment

14 June 2024 13:48

IMmotion010 trial: KIM-1 and disease-free survival in RCC

Presented By

Prof. Laurence Albiges, Institut Gustave Roussy, France

Trial

Phase 3, IMmotion010

Conference

ASCO 2024

13 June 2024 15:07

What’s new in clinical dermatology?

Presented By

Dr Tamar Nijsten, Erasmus University Medical Centre, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:31

Improving risk classification in cutaneous squamous cell carcinoma

Presented By

Dr Marlies Wakkee, Erasmus MC Rotterdam, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 12:54

Ins and outs of tumour-infiltrating lymphocytes therapy in metastatic melanoma

Presented By

Dr Tom Seijkens, Netherlands Cancer Institute, the Netherlands

Conference

DDD 2024

31 May 2024 12:40

No cardioprotective effect of ACE inhibitors in patients with cancer

Presented By

Dr David Austin, South Tees Hospitals, UK

Trial

Phase 3, PROACT

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 14:06

Second-line therapy for multiple myeloma: Where we are now?

Presented By

Dr Francesca Gay, University of Torino, Italy

Conference

EMN 2024

23 April 2024 11:56

The state of toxicities for immunotherapy for multiple myeloma

Presented By

Dr Alfred Garfall, University of Pennsylvania, PA, USA

Conference

EMN 2024

23 April 2024 11:39

Early multiple myeloma: where are immunotherapies headed?

Presented By

Dr Elias K. Mai, University Hospital Heidelberg, Germany

Conference

EMN 2024

23 April 2024 11:34

How does resistance arise for immunotherapy in relapsed/refractory multiple myeloma?

Presented By

Dr Nizar Bahlis, University of Calgary, Canada

Conference

EMN2024

23 April 2024 11:27

Functional imaging to complement bone marrow MRD in multiple myeloma

Presented By

Dr Elena Zamagni, Bologna University, Italy

Conference

EMN 2024

22 April 2024 13:04

Mass spectrometry detection of MRD for patients with multiple myeloma

Presented By

Dr Joannes F. M. Jacobs, Radboud University Medical Center, the Netherlands

Conference

EMN 2024

22 April 2024 13:02

Is MRD testing ready for prime time in multiple myeloma?

Presented By

Prof. Edward A. Stadtmauer, University of Pennsylvania, PA, USA

Conference

EMN 2024

22 April 2024 12:59

Managing transplant-ineligible elderly and frail patients with multiple myeloma

Presented By

Dr Salomon Manier, University of Lille, France

Conference

EMN 2024

22 April 2024 12:57

Treatment should be tailored to frailty status in patients with transplant-ineligible newly diagnosed multiple myeloma

Presented By

Dr Sara Bringhen, University of Torino, Italy

Conference

EMN 2024

22 April 2024 12:53

Interview: Advancing Myeloma Care

Expert

Prof. Monique Minnema, UMC Utrecht, the Netherlands

19 March 2024 14:42

Impact of Treatment on Multiple Myeloma Outcomes: Real-World Experience

19 March 2024 14:29

Determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies

18 March 2024 09:53

Recommendation to screen for colorectal cancer by full colonoscopy in first-degree relatives of patients

18 March 2024 09:42